Lipitor Generics Watch: FDA Has Yet To Approve ANDA For The World's #1 Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan had pointed to June 28 as the earliest date FDA could approve atorvastatin ANDAs; the agency is continuing discussions with Ranbaxy about its exclusivity status.
You may also be interested in...
Can Watson Give Birth To A Pregnancy Franchise As It Helps Lay Lipitor To Rest?
Watson is progressing on a multi-year effort to diversify beyond its core U.S. generics business into branded drugs and international markets.
Countdown To Generic Lipitor: Watson Expects Pfizer To Retain 40% Market Share For Six Months
Watson, which will launch an authorized generic Nov. 30, says Pfizer is trying to get pharmacy benefit managers to give Lipitor preferred formulary status.
Countdown To Generic Lipitor: Watson Expects Pfizer To Retain 40% Market Share For Six Months
Watson, which will launch an authorized generic Nov. 30, says Pfizer is trying to get pharmacy benefit managers to give Lipitor preferred formulary status.